DNLI Key Statistics, Chart & Performance
The current stock price of DNLI is 19.47 USD. In the past month the price increased by 18.86%. In the past year, price decreased by -22.12%.
DNLI Latest News, Press Relases and Analysis
DNLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About DNLI
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 486 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Company Info
DENALI THERAPEUTICS INC
161 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Ryan J. Watts
Employees: 486
Phone: 16508668547
DENALI THERAPEUTICS INC / DNLI FAQ
What does DENALI THERAPEUTICS INC do?
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 486 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
What is the current price of DNLI stock?
The current stock price of DNLI is 19.47 USD. The price increased by 0.36% in the last trading session.
Does DENALI THERAPEUTICS INC pay dividends?
DNLI does not pay a dividend.
What is the ChartMill technical and fundamental rating of DNLI stock?
DNLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for DNLI stock?
DENALI THERAPEUTICS INC (DNLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
Is DENALI THERAPEUTICS INC (DNLI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DNLI.
What is the employee count for DNLI stock?
DENALI THERAPEUTICS INC (DNLI) currently has 486 employees.
DNLI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DNLI. When comparing the yearly performance of all stocks, DNLI turns out to be only a medium performer in the overall market: it outperformed 57.02% of all stocks.
DNLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DNLI. DNLI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DNLI Financial Highlights
Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -1.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.07% | ||
| ROE | -46.63% | ||
| Debt/Equity | 0.01 |
DNLI Forecast & Estimates
25 analysts have analysed DNLI and the average price target is 32.23 USD. This implies a price increase of 65.55% is expected in the next year compared to the current price of 19.47.
For the next year, analysts expect an EPS growth of -14.65% and a revenue growth -99.18% for DNLI